Enovis Co. (NYSE:ENOV) Shares Acquired by Oppenheimer Asset Management Inc.

Oppenheimer Asset Management Inc. boosted its holdings in Enovis Co. (NYSE:ENOV) by 38.2% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 9,876 shares of the company’s stock after purchasing an additional 2,731 shares during the quarter. Oppenheimer Asset Management Inc.’s holdings in Enovis were worth $446,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in the business. Scout Investments Inc. acquired a new position in shares of Enovis during the 1st quarter valued at about $6,116,000. Price T Rowe Associates Inc. MD raised its stake in Enovis by 88.8% during the first quarter. Price T Rowe Associates Inc. MD now owns 381,118 shares of the company’s stock worth $23,802,000 after purchasing an additional 179,276 shares during the period. UBS Group AG boosted its holdings in shares of Enovis by 1,060.8% in the 4th quarter. UBS Group AG now owns 333,510 shares of the company’s stock valued at $18,683,000 after purchasing an additional 304,779 shares during the last quarter. Tributary Capital Management LLC grew its stake in shares of Enovis by 15.6% during the 1st quarter. Tributary Capital Management LLC now owns 338,371 shares of the company’s stock valued at $21,131,000 after buying an additional 45,745 shares during the period. Finally, Quadrature Capital Ltd increased its holdings in shares of Enovis by 175.5% during the 4th quarter. Quadrature Capital Ltd now owns 34,160 shares of the company’s stock worth $1,913,000 after buying an additional 21,760 shares during the last quarter. 98.45% of the stock is currently owned by hedge funds and other institutional investors.

Enovis Stock Performance

Enovis stock opened at $43.65 on Friday. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.08 and a current ratio of 2.26. Enovis Co. has a one year low of $39.98 and a one year high of $65.03. The stock’s 50 day moving average price is $44.73 and its 200 day moving average price is $50.05. The firm has a market capitalization of $2.39 billion, a PE ratio of -29.10 and a beta of 1.92.

Enovis (NYSE:ENOV) last posted its earnings results on Wednesday, August 7th. The company reported $0.62 EPS for the quarter, topping analysts’ consensus estimates of $0.59 by $0.03. The business had revenue of $525.20 million for the quarter, compared to analysts’ expectations of $525.99 million. Enovis had a negative net margin of 4.73% and a positive return on equity of 4.06%. The business’s revenue for the quarter was up 22.6% compared to the same quarter last year. During the same period in the previous year, the company posted $0.61 earnings per share. As a group, sell-side analysts expect that Enovis Co. will post 2.7 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have issued reports on ENOV. Needham & Company LLC lowered their price target on Enovis from $82.00 to $65.00 and set a “buy” rating for the company in a research report on Thursday, August 8th. JPMorgan Chase & Co. decreased their target price on Enovis from $53.00 to $50.00 and set a “neutral” rating for the company in a report on Thursday, August 8th. Finally, Evercore ISI reduced their price target on shares of Enovis from $70.00 to $62.00 and set an “outperform” rating on the stock in a research report on Tuesday, July 2nd. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $69.13.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.